Language
English
عربي
Tiếng Việt
русский
français
español
日本語
한글
Deutsch
हिन्दी
简体中文
繁體中文
API
Home
How To Use
Language
English
عربي
Tiếng Việt
русский
français
español
日本語
한글
Deutsch
हिन्दी
简体中文
繁體中文
Home
Detail
@kxngwxzard: W Ba3d El Shoghla Di B Sa3a🕵️♂️ #سحبت_سلاحي #بعد_الشغله_دي_بساعه❌💃😂 #حمو_بيكا #ميسرة #الصورص #فيجو_الدخلاوي #اسلام_المصري #KX
KX🧟♂️
Open In TikTok:
Region: EG
Tuesday 17 November 2026 14:20:00 GMT
5759
187
0
21
Music
Download
No Watermark .mp4 (
112.15MB
)
Watermark .mp4 (
112.15MB
)
Music .mp3
Comments
There are no more comments for this video.
To see more videos from user @kxngwxzard, please go to the Tikwm homepage.
Other Videos
#eşrefrüya #eşreftek #keşfet #foryoupage #foryou
Your liver could be quietly struggling — and a new GLP-1 cousin just posted big numbers. Efinopegdutide, an investigational once-weekly GLP-1 + glucagon drug from Merck, resolved MASH — a serious form of fatty liver disease — in 63% of people at the 7 mg dose vs 13% on placebo, in a 52-week Phase 2b trial of 386 adults. Results were presented Nov 9 at The Liver Meeting and published in The Lancet. About 1 in 20 people worldwide may have MASH, and it often has no symptoms. It's NOT approved yet — it holds FDA Fast Track status, and the most common side effects were nausea and vomiting. This is research news, not medical advice — if liver health is on your mind, talk to your doctor about screening and options. Did you know GLP-1s were being tested for liver disease? #GLP1 #MASH #LiverHealth #GLTrax
🌊 entrando na onda com a própria @NandaTsunami 💖
الفنـان الإمام الجموعي|| انا ماشي معاك #تصاميم_أغاني_سودانية #تصاميم_فيديوهات🎶🎤🎬
About
Robot
API
Legal
Privacy Policy